Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy
Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy
复制标题
胃癌全身化疗及术后腹腔注射治疗
作者：
P. Crookes;C. Leichman;L. Leichman;M. Tan;L. Laine;S. Stain;J. Baranda;Y. Casagrande;S. Groshen;H. Silberman
由于只有大约50%的胃癌是可切除治愈的，作者假设有效的全身术前（新辅助）化疗，旨在减小原发肿瘤的大小和范围，根除远处的显微疾病，可能会增加可切除率，并比单独的术后（辅助）治疗对生存率有更大的影响。此外，由于腹腔是胃癌成功切除后最常见的首次复发部位，腹腔化疗似乎是术后（辅助）治疗的合理选择。
Because only approximately 50% of gastric carcinomas are resectable for cure, the authors hypothesized that effective systemic preoperative (neoadjuvant) chemotherapy, aimed at decreasing the size and extent of the primary tumor and eradicating distant microscopic disease, may increase the rate of resectability and have a greater impact on survival than postoperative (adjuvant) treatment alone. In addition, because the peritoneal cavity is the most common site of first recurrence after successful gastric cancer resection, intraperitoneal (IP) chemotherapy seemed a logical choice for postoperative (adjuvant) treatment.
胃癌切除患者术后辅助腹腔注射顺铂和氟尿嘧啶以及全身氟尿嘧啶化疗的 II 期试验。
DOI：
10.1200/jco.1993.11.3.425
发表时间：
1993
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Atiq,OT;Kelsen,DP;Shiu,MH;Saltz,L;Tong,W;Niedzwiecki,D;Trochanowski,B;Lin,S;Toomasi,F;Brennan,M
通讯作者：
Brennan,M